Clinical trial

Assessment of the Effects of Tegaserod in the Management of Gastroesophageal…

NCT00171418 · Novartis, Industry · Completed

Key facts

NCT number NCT00171418
Title Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).
Official title Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).
Lead sponsor Novartis, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Gastroesophageal Reflux Disease (GERD)
Intervention type Drug
Interventions Tegaserod
Enrollment 54
Start date Jun 1, 2003
Completion Feb 1, 2005
First posted Sep 15, 2005
Last update posted Jan 28, 2008
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies